Free tool
FAERS Monitor: Otulfi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761379 or its brand name (Otulfi, Ustekinumab-Aauz). Reports on generic versions are filed under their own applications.
Reports
17
Serious
11
65% of reports
Hospitalization
4
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pain3
- accidental exposure to product2
- anxiety2
- death2
- drug ineffective2
- eosinophilic oesophagitis2
- exposure via skin contact2
- fatigue2
- product use in unapproved indication2
- treatment failure2
- abdominal discomfort1
- acute kidney injury1
- blindness1
- blood chloride decreased1
- blood sodium decreased1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 6 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eosinophilic oesophagitis | 2 | 894.2 | 243.1 | 1,002 |
| blood chloride decreased | 1 | 480.0 | 71.7 | 119 |
| exposure via skin contact | 2 | 95.5 | 26.0 | 105 |
| blood sodium decreased | 1 | 65.7 | 9.8 | 15 |
| blindness | 1 | 30.4 | 4.5 | 7 |
| treatment failure | 2 | 29.9 | 8.1 | 31 |
| accidental exposure to product | 2 | 24.0 | 6.5 | 24 |
| product use in unapproved indication | 2 | 10.0 | 2.7 | 9 |
| anxiety | 2 | 8.7 | 2.4 | 7 |
| acute kidney injury | 1 | 8.1 | 1.2 | 1 |
| abdominal discomfort | 1 | 7.4 | 1.1 | 1 |
| painSignal | 3 | 6.0 | 2.2 | 8 |
| fatigue | 2 | 3.2 | 0.9 | 1 |
| death | 2 | 2.9 | 0.8 | 1 |
| drug ineffective | 2 | 1.9 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.